Slide 1: Teleflex Incorporated Company Overview
TELEFLEX INCORPORATED COMPANY OVERVIEW Exhibit 99.1
Slide 2: Forward-Looking Statements/Additional Notes
2 2 2 Forward-Looking Statements/Additional Notes This presentation and our discussion contain forward-looking information and statements including, but not limited to, upcoming 2010 Medical Segment product launches; forecasted 2010 revenue, gross margin, operating margin, diluted earning per share
Slide 3: Teleflex Incorporated (NYSE: TFX)
3 Teleflex Incorporated (NYSE: TFX) Global medical technology company with leading market positions Critical Care Vascular access, anesthesia, respiratory, and urology Surgical Care Surgical instruments, sutures and ligation Cardiac Care Intra-aortic balloon pumps and catheters A 65+ year old Compan
Slide 4: TFX's Balanced Global Revenue
4 TFX's Balanced Global Revenue Medical Aerospace Commercial 0.77 0.1 0.13 Americas EMEA Asia Pacific 0.59 0.35 0.06 2009 Revenue = $1,868 Million
Slide 5: Leveraging TFX's Global Presence
5 Leveraging TFX's Global Presence Denotes major Medical facilities Denotes major Aerospace facilities Denotes major Commercial facilities Strong global brands Global channel with sales or distribution in over 140 countries Low-cost manufacturing footprint ~ 12,600 Employees worldwide
Slide 6: Medical Device Industry Overview
6 Medical Device Industry Overview Critical Care Surgical Care Cardiac Care OEM 0.28 0.29 0.02 0.41 Addressable Market Size Sales = $17.3 billion 1 Market Drivers Global demographics Aging population Rising standard of living in emerging markets Increasing demand for medical technology Global health
Slide 7: TFX - Competitive Advantages
7 TFX - Competitive Advantages Diversified global medical device company - not dependent upon any one procedure Significant presence in highly-engineered, single-use disposable medical technology markets Global sales platform - ~ 50% of medical revenues outside U.S Acquired and built a variety of we
Slide 8: Executing for Growth
8 EXECUTING FOR GROWTH
Slide 9: 2009 Revenue by Medical Segment, Brands and Market Share
2009 Revenue = $1,435 Million Critical Care - 65% Surgical Care - 20% Cardiac Care - 5% OEM - 10% Arrow, Rusch, HudsonRCI, Gibeck, Sheridan ~ 19% ~ $4.9 Billion Deknatel, Pleur-evac, Pilling, Taut, Weck ~ 6% ~ $5.0 Billion Arrow ~ 27% ~ $0.3 Billion Beere Medical, KMedic, SMD, Deknatel, TFX OEM ~ 2%
Slide 10: Critical Care
10 Critical Care Vascular Access Respiratory Urology Anesthesia 0.45 0.18 0.15 0.22 North America EMEA Asia / Latin America 0.5 0.37 0.13 2009 Revenue Sales = $939 million Key Products Central Venous Catheters Peripherally Inserted Central Catheters Dialysis Access Products Endotracheal Tubes Epidur
Slide 11: Surgical Care
11 Surgical Care North America EMEA Asia / Latin America 0.52 0.37 0.11 2009 Revenue Sales = $261 million Key Products Vessel Ligation Products Skin Staplers & Electrosurgical Devices Diverse / High-Quality / Customized Sutures ENT & CVT Instruments General Surgical Tools Laparoscopic Instruments Bl
Slide 12: Cardiac Care
12 Cardiac Care North America EMEA Asia / Latin America 0.36 0.43 0.21 2009 Revenue Sales = $71 million Key Products Intra-Aortic Balloon Pump Intra-Aortic Balloon Catheters Further penetration of emerging markets Technology innovation Aging population Pumps Catheters Other 0.25 0.69 0.06 Growth Dri
Slide 13: OEM
13 OEM 2009 Revenue Sales = $150 million Key Products Specialty Sutures Performance Fibers & Resins Precision Extrusion Catheter Fabrication Precision-Machined Implants & Instruments Orthopedic & Spinal Instruments Technology innovation Speed to market Demographics Increased regulatory scrutiny on s
Slide 14: Investing in Growth
14 INVESTING IN GROWTH
Slide 15: Infection Prevention
INFECTION PREVENTION Vascular Access Anesthesia Urology Improving outcomes by reducing infection, providing less invasive products supporting patient and provider safety VAP prevention UTI prevention Surgery SSI prevention Respiratory VAP prevention ARROWg+ard Blue Plus(r) CVC Teleflex ISIS CRBSI pr
Slide 16: New Product Introduction Update
16 New Product Introduction Update Launched in First Quarter 2010 Anesthesia: Teleflex ISIS TM HVT TM endotracheal tube Surgical: Deklene Maxx specialty cardiovascular suture Respiratory: Combined HEPA / HME Upcoming 2010 Product Launches Vascular Access: Anti-microbial coated PICC Vascular Access:
Slide 17: Clinical Education
17 Clinical Education A partnership with providers Commitment to solving challenges of changing healthcare Hands-on experience Access to leading healthcare experts and key opinion leaders Programs encompass Conferences and key note speakers Workshops Discussion panels Clinical consulting on products
Slide 18: Non-Medical Segment Business Review
18 NON-MEDICAL SEGMENT BUSINESS REVIEW
Slide 19: Aerospace
19 Aerospace 2009 Revenue Sales = $185 million Key Products Cargo-loading systems for wide-body aircraft Cargo-loading for narrow-body aircraft Containers Actuators Pallets Increase in air travel and flight hours Boeing 747-8 platform Airbus 330/340/350 platforms High-margin aftermarket sales Passen
Slide 20: Commercial
20 Commercial 2009 Revenue Sales = $248 million Key Products Controls & Cables Steering Systems & Instrumentation Hoses & Engine Drive Parts Wire & synthetic rope Hardware & wire rope installation services Global economy Expansion of oil exploration Marine Driver Controls & Engine & Drive Parts Rigg
Slide 21: Financial Review
FINANCIAL REVIEW Teleflex:
Slide 22: Q1'10 Financial Summary
22 Q1'10 Financial Summary Dollars in Millions, except per share 1 = Amount shown reflects percentage change versus prior year period. 2 = See reconciliation tables appended to this presentation for details regarding adjustments.
Slide 23: Q1'10 Segment Summary
23 Q1'10 Segment Summary 1 = Amount shown reflects percentage change versus prior year period. 2 = See reconciliation tables appended to this presentation for details regarding adjustments.
Slide 24: 2010 Financial Outlook
24 2010 Financial Outlook Dollars in Millions, except per share 1 = Amount shown reflects percentage change versus prior year period. 2 = See reconciliation tables appended to this presentation for details regarding adjustments.
Slide 25: Strategic Objectives / Business Development
25 STRATEGIC OBJECTIVES / BUSINESS DEVELOPMENT
Slide 26: Business Development Matrix
26 Business Development Matrix Expand Markets / Increase Scale / Leverage Competitive Advantages Co-promotion Product / Technology Acquisition Licensing Partnering Infrastructure Global Brands Distribution Technology
Slide 27: Longer-term Growth and Profitability Objectives
27 Longer-term Growth and Profitability Objectives Within the next five years, the Company is targeting the achievement of the following objectives: Consolidated organic revenue growth of approximately 5% Consolidated gross margins of approximately 55% Consolidated research and development expense o
Slide 28: Investment Opportunity
28 INVESTMENT OPPORTUNITY
Slide 29: TFX - Positioned for Value Creation
29 Committed to becoming pure-play global med-tech company Sales and Marketing investment Focus on improving patient and provider outcomes R&D investment Technology driven Infection prevention and patient safety features Pipeline development Product-line extensions Leverage Global brands Licensing /
Slide 30: Appendix
Teleflex:
Slide 31: Appendices A-D: Reconciliations
31 Appendix A - Reconciliation of Teleflex Gross Profit and Margins Appendix B - Reconciliation of Teleflex Operating Profit and Margins Appendix C - Reconciliation of First Quarter EPS from Continuing Operations Note: Q1'09 losses and other charges includes loss on sale of Gauge business of $1.6m,
Slide 32: Appendices E-H: Reconciliations
32 Appendix E - Reconciliation of Teleflex Cash Flow from Continuing Operations Appendix F - Reconciliation of Medical Operating Profit and Margins Appendix G - Reconciliation of Full Year 2009 Teleflex Gross Profit and Margins Appendix H - Reconciliation of Full Year 2009 Teleflex Operating Profit
Slide 33: Appendices I-L: Full Year 2009 Reconciliations
33 Appendix I - Reconciliation of Full Year 2009 EPS from Continuing Operations Note: FY'09 losses and other charges includes loss on sale of Gauge business of $1.6m, net of tax and integration costs of $1.6m, net of tax Appendix J - Reconciliation of Full Year 2009 Cash EPS Including Special Charge